The consequences of inhibition of nitric oxide synthesis on local CBF and glucose utilisation have been studied in the conscious rat using the specific nitric oxide synthase inhibitor Ng-nitro-L-arginine methyl ester (L NAME; 30 mg kg-I i.v.). Local CBF and glucose utili sation were assessed with the [14C]iodoantipyrine and the 2-deoxY-D-[14C]glucose autoradiographic techniques, re spectively. L-NAME induced prolonged (>3 h) reduc tions in local CBF throughout the CNS with concomitant increases in arterial blood pressure. For example, 1 h post L-NAME, CBF dropped from 79 ± 4 to 45 ± 1 mlIOO g-I min-I in cerebellum, from 76 ± 4 to 47 ± 2 mll00 g-I min -1 in medulla oblongata, and from 117 ± 6 to 72 ± 2 ml 100 g-I min -I in cortex. L-NAME produced sus tained elevations (e.g., 46 ± 2 mm Hg at Ih after bolus Nitric oxide (NO) is synthesised from L-arginine by the enzyme NO synthase. NO is a nonpolar gas with a half-life of a few seconds, which can readily diffuse across cell membranes. Certain analogues of L-arginine, such as Nl-nitro-L-arginine methyl ester (L-NAME), competitively inhibit the synthesis of NO and consequently have been used extensively to try to elucidate the major physiological actions of this endogenous molecule. NO synthesised in en dothelium of peripheral blood vessels relaxes vas cular smooth muscle and prevents platelet adhesion and aggregation via stimulation of soluble guanyl cyclase. NO synthase appears to be tonically active in vivo, providing the peripheral vasculature with a Abbreviations used: 2-DG , 2-deoxY-D-glucose ; L-NAME , NIl-nitro-L-arginine met h yl ester. 985 administration) in mean arterial blood pressure through out the period evaluated. Despite evidence implicating nitric oxide in neuronal signalling, L-NAME did not sig nificantly influence CNS functional activity, as measured by local rates of glucose utilisation, in any neuroanatom ical region examined. Consequently, the normal ratio of blood flow to glucose use throughout the brain was sig nificantly reduced in the presence of L-NAME, although the hierarchy of blood flow levels in different neuroana tomical regions was preserved. These results are consis tent with the involvement of nitric oxide in the tonic con trol of cerebral tissue perfusion. Key Words: Cerebral blood flow-2-DeoxY-D-glucose-Nitric oxide-Ng Nitro-L-arginine methyl ester.
Nitric oxide (NO) is synthesised from L-arginine by the enzyme NO synthase. NO is a nonpolar gas with a half-life of a few seconds, which can readily diffuse across cell membranes. Certain analogues of L-arginine, such as Nl-nitro-L-arginine methyl ester (L-NAME), competitively inhibit the synthesis of NO and consequently have been used extensively to try to elucidate the major physiological actions of this endogenous molecule. NO synthesised in en dothelium of peripheral blood vessels relaxes vas cular smooth muscle and prevents platelet adhesion and aggregation via stimulation of soluble guanyl cyclase. NO synthase appears to be tonically active in vivo, providing the peripheral vasculature with a administration) in mean arterial blood pressure through out the period evaluated. Despite evidence implicating nitric oxide in neuronal signalling, L-NAME did not sig nificantly influence CNS functional activity, as measured by local rates of glucose utilisation, in any neuroanatom ical region examined. Consequently, the normal ratio of blood flow to glucose use throughout the brain was sig nificantly reduced in the presence of L-NAME, although the hierarchy of blood flow levels in different neuroana tomical regions was preserved. These results are consis tent with the involvement of nitric oxide in the tonic con trol of cerebral tissue perfusion. Key Words: Cerebral blood flow-2-DeoxY-D-glucose-Nitric oxide-Ng Nitro-L-arginine methyl ester.
relaxing factor that controls vessel calibre and con sequently the extent of blood flow through periph eral vascular beds.
NO may also be an important mediator of cere brovascular control. There are at least three sources of NO in the CNS, endothelial, neuronal, and glial, and all may have some influence over cerebrovascular calibre and ultimately CBF. Endo thelial NO synthase would seem the most likely source of vasorelaxant NO because of the close proximity to the smooth muscle and the fact that hypoxia-induced vasorelaxation is lost in endothe lium-denuded or methylene blue-treated isolated cerebral vessels (Pearce et aI., 1989) . However, perivascular nerve fibres, immunoreactive for NO synthase, have also been reported and neurally me diated release of NO shown to be vasorelaxant (Bredt et al., 1990; Toda and Okamura, 1991) . Fi nally, astrocytes, which via specialised endfoot pro cesses are intimately associated with the cere brovasculature, are also capable of releasing NO, which influences the calibre of underlying vessels (Murphy et aI., 1991) . Reported reductions in CBF within minutes of intravenous administration of a nitric oxide synthase inhibitor (Tanaka et aI., 1991) provide further support for NO as an important me diator of cerebrovascular control.
In CNS neurones NO serves as an important messenger molecule in the regulation of cell func tion and cellular communication (Garthwaite et aI., 1988; Bredt and Synder, 1989; Moncada et aI., 1991; Vincent and Hope, 1992) . In addition, NO mediates the stimulation of cyclic GMP induced by excitato ry amino acids in rat cerebellum (Wood et aI., 1990) and N-methyl-D-aspartate-induced excitotoxic damage in cortical culture (Dawson et aI., 1991) . Consequently, NO may also be involved in CNS function.
The aim of this study was to assess the impor tance of endogenous NO both in the control of the cerebral circulation and for neuronal function in the eNS, as reflected in local rates of glucose utilisa tion.
MATERIALS AND METHODS
All investigations were performed on male Sprague Dawley rats (347 ± 37 g; Harlan Olac Ltd., Bicester, U.K.). Anaesthesia was induced with 5% halothane in a 70:30 nitrous oxide/oxygen gas mixture and maintained by lowering the halothane to 0.75-1%. �olythene can . nu lae were inserted into both femoral vems and arterIes, with incision sites infiltrated with local anaesthetic prior to suturing and a loose-fitting abdominal-pelvic plaster cast applied for restraint. The animals were maintained normothermic by external heating and allowed to recover from the anaesthetic for at least 2 h before measurement of CBF or glucose utilisation was commenced. Blood pressure, heart rate, and rectal temperature were moni tored throughout the experimental period and blood sam ples taken to monitor Pac02' Pao2, and whole-blood pH prior to and post drug administration.
Cardio-and cerebrovascular effects of L-NAME: dose-response
The cardiovascular and cerebrovascular effects of in travenous L-NAME were investigated at 0.3 ,3, and 30 mg kg-I with CBF measured 30 min following drug admin istration (1 ml kg-I i.v. L-NAME; Sigma, U.K.). CBF measurements were performed with a 30-s ramped infu sion of [14C]iodoantipyrine (10 /-l-Ci in 1.5 ml) using the method described by Sakurada et ai. (1978) . During the infusion, 15-18 timed samples of arterial blood were col lected from the femoral line on preweighed filter discs, and the drop rate recorded. The rat was killed by decap itation at the end of the infusion and the kill time re corded. The brain was quickly removed to a chilled glass plate and a number of neuroanatomically identified re gions dissected out. Tissue and blood samples were weighed and e4C] concentrations determined, after solu bilisation, by liquid scintillation analysis. CBF values were calculated from the partition coefficient for iodoan-J Cereb Blood Flow Metab, Vol. 13, No. 6, 1993 tipyrine and the blood and brain radioisotope concentra tion histories.
Time course of effects of L-NAME on CBF
The temporal effect of L-NAME on CBF was investi gated using the [14C]iodoantipyrine method described above. CBF measurements were performed at 15, 30, 60, and 180 min following intravenous L-NAME administra tion (3 0 mg kg-I, 1 ml kg-I).
Neuroanatomical distribution of effect of L-NAME onCBF The effect of L-NAME on CBF in distinct neuroana tomical regions was examined 30 min post L-NAME (30 mg kg-I i. v.) using [14C]iodoantipyrine autoradiography. The procedure was similar to that for the dose-response study, with the exception that a higher concentration of iodoantipyrine (50 /-l-Ci) was used. Following decapitation the brain was quickly removed and frozen in isopentane chilled to -42°C with dry ice. Twenty-micron coronal sections were cut on a cryostat at -20°C, mounted onto glass slides, and apposed to x-ray film (Kodak GRL) for 14 days along with a set of [14C] standards (44-1175 nCi g-I). Optical densities of regions of interest and the ra dioactive standards were measured on a computer-based densitometer (Quantimet 970; Cambridge Instruments).
At least 12 densitometric determinations were made for each region using several autoradiographic images from the same neuroanatomical region. CBF was calculated in each region from brain tissue radioisotope concentration, the partition coefficient for iodoantipyrine, and the plasma history of the isotope (Sakurada et aI., 1978) .
Local cerebral glucose utilisation after L-NAME Fifteen minutes after L-NAME injection (30 mg kg-I i.v., 1 ml kg-I), the measurement of glucose utilisation was initiated by intravenous administration of 50 /-l-Ci 2-deoxY-D-e 4C]glucose (e 4C]2-DG) as a bolus. Fourteen timed arterial blood samples, taken throughout the fol lowing 45 min, were centrifuged immediately and the plasma assayed for [14C] activity by liquid scintillation counting and for glucose concentration (Glucose Analy ser 2; Beckman). Approximately 35 min following 2-DG administration, a sample of arterial blood was analysed for PaC02 and pH levels (168 pH/Blood Gas System; Corning). The rat was decapitated 45 min after isotope administration and the brain processed as for [14C]iodo antipyrine autoradiography. Local cerebral glucose use, measured in the same neuroanatomical regions examined for blood flow autoradiography, was calculated using densitometric measurement of tissue [14C] concentration, the plasma histories of e4C] and glucose, and the opera tional equation for the technique (Sokoloff et al., 1977) .
Statistical analysis
Data are presented as means ± SD. Statistical analysis of haemodynamic and independent CBF and glucose use results involved analysis of variance and Student's t test with a Bonferroni correction for multiple comparisons where appropriate. The relationship between glucose use and CBF in drug-and vehicle-treated rats was assessed by repeated measures analysis of variance carried out on the logs of the measured responses with "type of vari able" regarded as a grouping factor and "brain region" regarded as a repeated measures trial factor (see McCul-loch et aI., 1982a) . Interregional differences in the mag nitude of the local CBF/local cerebral glucose utilisation ratio were examined in control data using the test of Greenhouse and Geisser (see McCulloch et aI., 1982a; Ford et aI., 1991) .
RESULTS

Haemodynamic effects of nitric oxide synthase inhibition
Intravenous L-NAME (0.3, 3, and 30 mg kg-1 in saline) gave rise to a significant and dose-related elevation in mean arterial pressure with a concom itant bradycardia (Table 1 ). Blood pressure rose by > 30 mm Hg within the first 5 min following the 30-mg kg-I dose with a peak effect at 1 h and ele vated blood pressure maintained over the 3-h dura tion of the experiment (Fig. O . At this dose L-NAME-treated animals showed some signs of se dation and exhibited a gradual reduction in their body temperature over the duration of the experi ment. Even with external heating, body tempera ture fell by 1 SC at 1 h postdrug (Table 2) and by >2°C by the end of experiments of 3-h duration. Administration of vehicle (saline) was without sig nificant haemodynamic effect ( Fig. 1 ) and did not influence body temperature or blood gases (Table  2) . A small but significant increase in plasma glu cose was recorded in the vehicle-treated rats.
Consequences of nitric oxide synthase inhibition on local CBF
L-NAME (0.3, 3, and 30 mg kg-I i.v.) induced a dose-related reduction in local CBF throughout the brain. CBF was measured in 10 dissected anatomi cal regions 30 min after intravenous L-NAME. Of these 10 neuroanatomical regions, a significant re duction in CBF was recorded in all 10 regions fol lowing 30 mg kg-I. With 3 mg kg-I L-NAME, re ductions in CBF reached statistical significance in four regions (i.e., cerebellum, hypothalamus, supe rior colliculus, and olfactory bulbs). Reductions in CBF induced by 0.3 mg kg-1 L-NAME did not reach statistical significance in any region exam ined. Figure 2 illustrates dose-related reductions in CBF from 6 of the 10 regions examined. The 30 mg kg -1 dose was subsequently used to study the time course of changes in CBF in response to L-NAME. CBF was measured in the same 10 anatomical re gions at 15, 30, 60, and 180 min after intravenous L-NAME or vehicle.
The bolus administration of L-NAME resulted in a prolonged, significant, and homogeneous reduc tion in CBF (Table 3 ; Fig. 3 ). CBF reductions were of a similar magnitude in all 10 neuroanatomical re gions examined (e.g., range of 37-43% at 3-h time point). In contrast to the L-NAME-induced in creases in blood pressure, which dropped from 30 ± 2.5% at 1 h post L-NAME to 19 ± 3.5% at 3 h post L-NAME (Fig. 1) , the reduction in CBF (Fig. 3) was well maintained and still maximal at 3 h postadmin istration (e.g., -37 ± 6 and -43 ± 4.5% in cere bellum at 1 and 3 h, respectively).
Effects of L-NAME on local cerebral glucose utilisation L-NAME (30 mg kg-I i.v.) did not alter signifi cantly the rate of glucose utilisation in any of the 13 neuroanatomical regions examined (Table 4) . The autoradiograms from L-NAME-treated rats were in distinguishable from those of vehicle-treated rats, and on detailed visual inspection no region could be identified as displaying focal alterations in local ce rebral glucose use.
Influence of L-NAME on relationship between CBF and glucose utilisation L-NAME-induced changes in CBF were also in vestigated autoradiographically to enable direct comparison of CBF and glucose utilisation in dis crete neuroanatomical regions following L-NAME or saline treatment.
As in the above study with tissue dissection, L-NAME produced a profound reduction in CBF in all the neuroanatomical regions examined in the au- Saline 9 135 ± 6 448 ± 37 -0 .4 ± 4 +7 ± 10 L-NAME (0 .3 mg kg-I ) 5 135 ± 4 449 ± 46 + 12 ± 2a -1 0 ± 10 L-NAME (3 mg kg-I ) 5 134 ± 1 462 ± 37 +2 9 ± 7a -9 9 ± 35a L-NAME (30 mg kg-I ) 6 131 ± 6 431 ± 30 +3 7 ± 8a -127 ± 26a
MAB P and he art rate pr ior to intravenous L-NAME or saline administration and t h e ch anges in t h ese pa rameters 30 min po st administration . Data are pr esented as means ± SO. a p < 0. 00 1 rep resents statistical significance using one-way analysis of variance and Student's unp aired t test wit h a Bonferroni correction for mUltip le comp arisons. toradiograms (Table 4 ). In contrast, there were no significant changes in local cerebral glucose utilisa tion in any of these regions (see Table 4 ). If local CBF is plotted against local cerebral glucose use for all the neuroanatomical regions examined, a clear relationship between the two parameters is appar ent in both drug-treated and control animals (Fig.  4) . It is also apparent that the CBF/glucose use ratio has been reset to a lower value in the L-NAME treated rats. This change in the flow/metabolism coupling ratio is highly significant (p < .008) and occurs homogeneously in all neuroanatomical re gions examined (analysis by repeated measures analysis of variance). Significant interregional differences in the CBF/ cerebral glucose use ratio could be demonstrated between regions in the control rats using Green house-Geisser (p = 0.001) and Huynh-Feldt (p = 0.0001) corrections. However, there is no evidence to suggest that this interregional heterogeneity was different between the control group and the group receiving the drug (Greenhouse-Geisser p > 0.46, Huynh-Feldt p > 0.49).
DIS CUSSION
The ability of cerebrovascular endothelium, neu ral tissue, and glia to generate NO predicts a diverse array of functions for this molecule in the CNS. The yl ester (L-NAME; 30 mg kg-1 Lv.; e) and saline (0) in conscious rats.
Data are means ± SO, expressed as change in blood pressure (ABP) and change in heart rate (AHR), with n = 6 for L-NAME-treated rats and n = 4 for saline controls. 'Sig nificant difference (p < 0.05) from the saline control using analysis of variance and Student's unpaired t test with a Bonferroni correction for multiple comparisons.
distribution of endothelial NO synthase appears to be homogenous throughout the cerebral circulation, while the parenchymal distribution has a clear het erogeneous distribution (F6rstermann et al., 1990) , with the highest NO synthase activity in the cere bellum, moderate levels in the hypothalamus and midbrain, and low activity in the medulla oblongata. Parenchymal NO is recognised as a neuronal messenger that is capable of both retrograde and anterograde signalling (Garthwaite et al., 1988; Schuman and Madison, 1991; McCall and Vallance, 1992) . For example, NO is a mediator of glutamate transmission, providing the link between receptor stimulation and increased production of cyclic GMP (Wood et aI., 1990) . Since the level of intracellular calcium required for NO synthesis is inhibitory to guanyl cyclase activity, it appears that NO travels from its site of synthesis to neighbouring cells to stimulate cyclic GMP (Knowles et al., 1989) .
In addition to post junctional production of NO, there is increasing evidence, in the periphery, for prejunctional synthesis and a neurotransmitter role for NO (for review see Garthwaite, 1991) , and this may also apply within the CNS. Toda and Okamura (1991) have reported NO synthase-positive perivas cular nerves around cerebral vessels that vasodilate via NO. In view of the possible pre-and postjunc tional synthesis and release of NO, its involvement TABLE 2. Effects ofNg-nitro-L-arginine methyl ester (L-NAME) on respiratory status and body temperature Rectal temp erature eC)
37 .0 ± 1.0 37 .1 ± 0.7 37 .0 ± 0.36 35 .5 ± 0.42 b
Ph ysiological pa rameters recorded pr ior to and I h following administration of L-NAME (30 mg kg -I i. v. ) or saline (1 ml kg-I ) in conscious rats. L-NAME did not significantly affect blood gas or pl asma glucose levels but did induce a small , significant reduction in body temp erature. Results are exp ressed as means ± SD. a p < 0.05 , b p < 0.001 using Student's pa ired t test . in mediating the effects of glutamate, and its influ ence on enzyme systems such as guanyl cyclase within the eNS, it is not unreasonable to assume that this molecule could have widespread effects on CNS function.
The C4C]2-DG technique provides comprehen sive assessment of function-related changes in glu cose use in vivo (Sokoloff et aI., 1977) . Since dy namic alterations in glucose use reflect, predomi nantly, activity in the axon terminals, this technique has become a powerful tool for the identification of both neuroanatomical structures and neuronal cir cuits affected by various physiological, pharmaco logical, and pathophysiological states (Sokoloff, 1981) . In the present study, we have employed [14C12-DG autoradiography to examine the func tional consequences of NO synthesis inhibition.
NO and function-related glucose use
Alterations in cerebral function, and hence oxy gen and glucose demand, promote changes in eBF to meet the energy requirements of the tissue (Kuschinsky and Wahl, 1978; Siesjo, 1978) . The ob- served decrease in CBF following L-NAME admin istration could therefore indicate a reduction of CNS function and energy demand. However, no significant change in glucose utilisation was found in any of the neuroanatomical regions examined, while eBF was found to be markedly reduced (Ta ble 4). The absence of any alteration in glucose use could be indicative of an inappropriate choice of drug (blood-brain barrier permeability) or its con centration. However, two lines of evidence refute this explanation. First, L-nitroarginine (the base form of L-NAME) crosses the blood-brain barrier more easily than other arginine analogues, and sys temic administration has been reported to result in inhibition of brain NO synthase activity in rats (Dwyer et aI., 1991) . Second, in the present study, this dosing regimen was sufficient to significantly reduce eBF throughout the brain and to cause a significant reduction in body temperature. This re duction in body temperature would appear to be a central action of the drug involving thermoregula tory centres in the brain. In support of this, NO synthesis inhibitors have been shown to attenuate 
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CBF data are pr esented as means ± SD (ml loo g-I min -I ) . Times are t h e times following L-NAME (30 mg kg-I ) or saline (1 ml kg-I ) administration wh en local CBF was measured . a p < 0.001, b p < 0.01 , "p < 0.05 rep resent statistical significance using Student's unp aired t test.
Temporal profile of N9-nitro-L-arginine methyl ester (L-NAME)-induced CBF changes in two neuroanatomical re gions of the CNS-the medulla (e) and the cerebellum (0).
Data are means ± SO, expressed as the change in CBF (LlCBF) following L-NAME treatment (30 mg kg -1 i.v.), with n = 5 for each region. The drug-induced reduction in CBF in both regions was statistically significant at all time points studied (see Table 2 ).
the thermogenic and hyperthermic effects of pros taglandin E 2 microinjections into rat anterior hypo thalamus (Amir et aI., 1991) . Hypothermia, per se, is known to depress functional activity and conse quently CBF (see Siesj6, 1978) . However, in re ports of significant reductions in glucose utilisation in response to hypothermia, body temperature was reduced to a much greater degree than was seen in the present study [e.g., -5.6°C in McCulloch et ai. (1982b) , -17°C in Palmer et ai. (1989) ]. The fact that there was no significant change in glucose use in the face of marked L-NAME-induced reductions in CBF does not, however, preclude an involvement for NO in CNS function. In fact, the current literature reveals a multitude of NO mediated effects within the CNS (Garthwaite, 1990; McCall and Vallance, 1992; Vincent and Hope, 1992) . Previous observations from 2-DG studies caution against the interpretation of negative find ings with 2-DG as indicative of a lack of involve ment in a particular response (e.g., McCulloch et aI., 1982c; Cudennec et aI., 1988) . The method av erages glucose use in a heterogeneous population of cell types in a given neuroanatomical area (e.g., af ferent neurones, interneurones, and glia). Since NO may produce different effects in each cell type, there may be no overall change in 2-DG uptake while functional activity at a cellular level may be radically altered when NO synthesis is inhibited. From the literature it is apparent that, depending on the enzyme system under study, NO can be either stimulatory or inhibitory (Garthwaite, 1990; McCall and Vallance, 1992; Vincent and Hope, 1992) , again adding to heterogeneous changes within a given area. Finally, since 2-DG reflects functional activity in a region over a prolonged period (45 min), an alternative explanation may be that the primary role of parenchymal NO is involvement in transient or phasic events rather than tonic or steady-state con ditions. It may be necessary, therefore, to pharma cologically or mechanically drive a particular path way or response involving NO, rather than blocking its synthesis in order to identify a role for NO in CNS function.
TABLE 4. Effect of Ng-nitro-L-arginine methyl ester (L-NAME) on CBF and cerebral glucose utilisation CBF Glucose utilisation (ml 100 g-I min -I) (fLmol 100 g-I min-I) Saline L-NAME Saline L-NAME (n = 7) (n = 6) (n = 6) (n = 6) Data are pr esented as means ± SD . a p < 0.05 , b p < 0.01 , cp < 0.001 rep resent statistically significant differences between saline and L-NAME (30 mg kg-I) data using Student's unp aired t-test. NO and cerebral tissue perfusion Cerebral endothelium (Pearce et al., 1989) , peri vascular nerves (Bredt et al., 1990; Toda and Oka mura, 1991) , parenchymal neurones (Gaily et al., 1990) , and glia (Murphy et al., 1991) all have the capacity to influence cerebrovascular tone via pro duction and release of NO. NO has, in fact, been proposed to represent the link molecule in flow/ metabolism coupling (GaIly et al., 1990) . This is based on the Ca 2 + dependence of NO synthase whereby NO production reflects increased synaptic activity and the ability of NO to diffuse across cell membranes to reach the nearby cerebral vascula ture.
Intravenous L-NAME administration (30 mg kg-I) results in a homogeneous and sustained re duction in CBF within the CNS concomitant with a significant hypertension and bradycardia peripher ally ( Fig. 1; Table 3 ). This result illustrates a tonic vasorelaxant influence of NO on both the cerebral and the peripheral circulations and is of the same order of magnitude as other studies using different NO � ynthase inhibitors (Tanaka et al., 1991; Kozmewska et al., 1992) . The L-NAME-induced re duction in CBF was not related to the reported level ? f NO s � nthase activity (Forstermann et al., 1990) In a partIcular neuroanatomical region, the profile of CBF changes being similar in areas of highest (cerebellum) and lowest (medulla oblongata) NO synthase activity (Fig. 3) . This finding supports the involvement of endothelial (but not parenchymal) NO as a tonic vasorelaxant influence on the cere bral circulation.
Relationship between local energy metabolism and local blood flow in brain
In the conscious rat, there is a highly significant correlation between the rate of glucose utilisation a � d blood flow in different cerebral structures (see Fig. 41 ' supporting the original concept of Roy and Shernngton (1890) that the regulation of the cere bral circulation is mediated by products of cerebral metabolism and that CBF is adjusted to match the lev � ls of local functional activity. Many centrally actIng drugs that primarily affect CNS functional activity evoke a secondary alteration in CBF in re sponse to drug-induced changes in metabolic de mand, for example, apomorphine (McCulloch et al., 1982a) and muscimol (Kelly and McCulloch, 1983) . Flow/metabolism coupling is maintained in the presence of these drugs and the CBF/cerebral glu cose use ratio unaltered. However, if the drug un der study has a direct effect on the cerebrovascula ture, changes in CBF can be recorded in the ab � ence . of . changes in cerebral glucose use, resulting In a slgmficant change in the normal ratio of blood flow to glucose use within the brain. This situation has been reported previously for both nimodipine (Mohamed et al., 1985) , which increases CBF and indomethacin (Pickard, 1981) , which reduces CBF.
A similar situation appears to exist for L-NAME where the results point to drug-induced effects on the cerebral vasculature rather than on tissue func tional activity. A significant (p < 0.008) resetting of the normal local CBF/local cerebral glucose use ra tio can be seen in all neuroanatomical regions of drug-treated animals. As in previous analyses of this type of data (McCulloch et al., 1982a) , there � as evidence for significant regional heterogeneity In the flow/metabolism ratio in control animals. However, the effect of L-NAME on this ratio was homogeneous throughout all brain regions.
In conclusion, the present results clearly indicate that, irrespective of the cerebral region examined or the normal level of blood flow or glucose utilisation, L-NAME administration resulted in a reduction in cerebral tissue perfusion. Although the relationship between blood flow and glucose use was fundamen tally altered after L-NAME (Fig. 4) , the hierarchy of blood flow levels in normal animals was maintained in the pres�n � e of the drug. Our data therefore sup port a tome Involvement for NO in the control of the cerebral circulation.
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